Download PDF
Nuklearmedizin 2009; 48(03): 89-98
DOI: 10.3413/nukmed-0221
Original article
Schattauer GmbH

Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer

Results after 874 patient-years of follow-up in the MSDS-trialKlinische Resultate der adjuvanten perkutanen Strahlentherapie bei differenziertem Schild-drüsenkarzinomErgebnisse der MSDS-Studie nach 874 Patient jahren Nachbeobachtungszeit
M. Biermann   *
1   Department of Radiology, Haukeland University Hospital, Bergen, Norway
,
M. K. Pixberg   *
2   Department of Nuclear Medicine, Münster University, Germany
,
B. Riemann   *
2   Department of Nuclear Medicine, Münster University, Germany
,
A. Schuck   *
3   Department of Radiooncology, Münster University, Germany
,
A. Heinecke   *
4   Department of Biometrics, Münster University, Germany
,
K. W. Schmid   *
5   Institute of Pathology and Neuropathology, University Hospital of Essen, West German Cancer Center, University of Duisburg-Essen, Germany
,
N. Willich   *
3   Department of Radiooncology, Münster University, Germany
,
H. Dralle   *
6   Department of General Surgery, University Halle-Wittenberg, Halle, Germany
,
O. Schober   *
2   Department of Nuclear Medicine, Münster University, Germany
› Author Affiliations
Further Information

Publication History

received: 25 October 2008

accepted in revised form: 26 March 2008

Publication Date:
22 January 2018 (online)

    Permissions and Reprints

Summary

Aim: Evaluate the clinical benefit of external beam radiotherapy (RTx) for locally invasive thyroid carcinoma with follicular cell differentiation (DTC). Patients, methods: The Multicentre Study on Differentiated Thyroid Cancer (MSDS) was planned as a prospective multicenter trial on the benefit of adjuvant RTx in locally invasive DTC (pT4; UICC 1997) with or without lymph node metastases and no known distant metastases. All patients were treated with thyroidectomy, 131I-therapy, and TSH-suppression and were randomized to receive additional RTx or not. In 4/2003 the trial became a prospective cohort study after only 45 of then 311 patients had consented to randomization. 351 of 422 patients met the trial's inclusion criteria. Age was 48 ± 12 years (mean ± SD). 25% were men. Tumours were papillary in 90% and follicular in 10%. Of 47 patients randomized or allocated to RTx, 26 actually received RTx. Results: Mean followup was 930 days. In an actual treatment analysis, 96% (25/26) of the RTx-patients reached complete remission (CR) vs. 86% in the non-RTx patients. Recurrences occurred in 0 vs. 3 % of patients: 6 reoperated for regional lymph node metastases, 1 tracheal invasion treated with tracheoplasty, 1 local invasion necessitating laryngectomy, 2 distant metastases (1 lung, 1 lung + bone). Serious chronic RTx toxicity occurred in 1/26 patients. Conclusion: The MSDS trial showed low mortality and recurrence rates and a weak benefit of RTx in terms of local control that did however not reach statistical significance. Routine RTx in locally invasive DTC can no longer be recommended .

Zusammenfassung

Ziel: Nachweis des klinischen Nutzens der adjuvanten perkutanen Strahlentherapie für lokal organüberschreitendes Schilddrüsenkarzinom mit Follikelzelldifferenzierung (DTC). Patienten, Methoden: Die Multizentrische Studie Differenziertes Schilddrüsenkarzinom (MSDS) war ge-plant als prospektive randomisierte Multizenterstudie zum Nutzen der adjuvanten perkutanen Radiatio bei lokal überschreitendem DTC (pT4; UICC 1997) mit oder ohne Lymphknotenmetastasen und ohne Fernmetastasen. Die Behandlung umfasste Thyreoidektomie, Radioiodablation und TSH-Suppressionsterapie sowie randomisiert die zusätzliche perkutane Radiatio. 4/2003 wurde die Studie als prospektive Kohortenstudie weitergeführt, nachdem lediglich 45 von 311 Patienten in die Randomisierung eingewilligt hatten. 351 von 422 erfüllten die Einschlußkriterien. Das mittlere Alter betrug 48 ± 12 Jahre (± Standardabweichung) bei einem Anteil männlicher Patienten von 25%. 90% der Tumoren waren papillär, 10% follikulär. Von 47 Patienten, die der Radiatio zugewiesen worden waren, wurden 26 bestrahlt. Ergebnisse: Die mittlere Nachsorgeperiode ist 930 Tage. 96% (25/26) der bestrahlten Patienten erreichen eine komplette Remission gegenüber 86% der nicht bestrahlten. Rezidive ereigneten sich bei keinem der bestrahlten und 3% der nicht-bestrahlten Patienten: 6 Rezidivoperationen wegen regionaler Lymphknotenmetastasen, 1 Trachealinvasion (behandelt mit Tracheoplastie) und 1 Lokalinvasion (Laryngektomie) und 2 Patienten mit Fernmetastasen (1 Lunge, 1 Lunge und Skelett). Bei 1/26 Patienten führte die Radiatio zu schwerer chronischer Toxizität. Schlussfolgerung: Die MSDS-Studie ergab niedrige Letalität und Rezidivraten. Eine geringgradige Verbesserung der lokalen Kontrolle durch die Radiatio war statistisch nicht signifikant. Die routinemäßige Radiatio kann bei lokal invasivem DTC nicht länger empfohlen werden.

Keywords

Thyroid cancer - external beam radiotherapy - radioiodine treatment - survival

Schlüsselwörter

Schilddrüsenkarzinom - perkutane Strahlentherapie - Radioiodablation - Überleben

* for the MSDS study group


 

  • References

  • 1 Biermann M, Pixberg M, Schuck A. et al. External beam radiotherapy. In: Biersack H-J, Grünwald F. (eds) Thyroid cancer. Heidelberg: Springer; 2005: 139-161.
    Google Scholar
  • 2 Biermann M, Pixberg MK, Dörr U. et al. Guidelines on radioiodine therapy for differentiated thyroid carcinoma. Impact on clinical practice. Nuklearmedizin 2005; 44: 229-237.
    PubMedGoogle Scholar
  • 3 Biermann M, Pixberg MK, Schuck A. et al. Multicenter Study Differentiated Thyroid Carcinoma (MSDS): Diminished acceptance of adjuvant external beam radiotherapy for differentiated thyroid carcinoma. Nuklearmedizin 2003; 42: 244-250.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Biermann M, Schober O. GCP-compliant management of the Multicentric Study Differentiated Thyroid Carcinoma (MSDS) with a relational database under Oracle 8i. Inform Biom Epidemiol Med Biol 2002; 33: 441-459.
    Google Scholar
  • 5 Chow SM, Law SC, Mendenhall WM. et al. Papillary thyroid carcinoma: Prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52: 784-795.
    CrossrefPubMedGoogle Scholar
  • 6 Deutsche Krebsgesellschaft. Malignant goiter. In: Junginger T, Hossfeld DK, Müller R-P (eds). Guidelines for the diagnosis and therapy of tumors of the gastrointestinal tract and the thyroid gland. Stuttgart: Thieme 1999; 204-213.
    Google Scholar
  • 7 Deutsche Krebsgesellschaft. Malignant thyroid tumors. Concise interdisciplinary guidelines 2000. Germering: Zuckschwerdt; 2000: 92-106.
    Google Scholar
  • 8 Dietlein M, Dressler J, Eschner W. et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer. Nuklearmedizin 1999; 38: 213-214.
    PubMedGoogle Scholar
  • 9 Dietlein M, Dressler J, Farahati J. et al. Guidelines for radioiodine therapy (RIT) in differentiated thyroid cancer. Nuklearmedizin 1999; 38: 221-222.
    PubMedGoogle Scholar
  • 10 Eichhorn W, Tabler H, Lippold R. et al. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 2003; 13: 949-958.
    CrossrefPubMedGoogle Scholar
  • 11 Esik O, Nemeth G, Eller J. Prophylactic external irradiation in differentiated thyroid cancer: a retrospective study over a 30-year observational period. Oncology 1994; 51: 372-379.
    CrossrefPubMedGoogle Scholar
  • 12 Farahati J, Reiners C, Stuschke M. et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996; 77: 172-180.
    PubMedGoogle Scholar
  • 13 Georgi P, Emrich D, Heidenreich P. et al. Radioiodine therapy of differentiated thyroid cancer. Recommendations of the Therapy Study Group of the German Society of Nuclear Medicine. Nuklearmedizin 1992; 31: 151-153.
    Google Scholar
  • 14 Hölzer S, Steiner D, Bauer R. et al. Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Eur J Nucl Med 2000; 27: 1465-1472.
    CrossrefPubMedGoogle Scholar
  • 15 Ito Y, Tomoda C, Uruno T. et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 2006; 30: 780-786.
    CrossrefPubMedGoogle Scholar
  • 16 Junginger T, Hartel W. Guidelines for the therapy of malignant thyroid tumors. Mitteilungen der Deutschen Gesellschaft für Chirurgie. 1996 3/1996.
    PubMedGoogle Scholar
  • 17 Kim TH, Yang DS, Jung KY. et al. Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys 2003; 55: 1006-1012.
    CrossrefPubMedGoogle Scholar
  • 18 Lee D, Cosmatos D, Marcial V. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etonidazole with radiotherapy alone for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1995; 32: 567-576.
    CrossrefPubMedGoogle Scholar
  • 19 Leisner B, Degelmann G, Dirr W. et al. Therapeutic results of malignant goiter 1960-1980. Significance of percutaneous radiotherapy in well differentiated carcinomas. Dtsch Med Wochenschr 1982; 107: 1702-1707.
    PubMedGoogle Scholar
  • 20 Lerch H, Schober O, Kuwert T, Saur HB. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-2075.
    CrossrefPubMedGoogle Scholar
  • 21 Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103: 2269-2273.
    CrossrefPubMedGoogle Scholar
  • 22 Rahbar K, Hutzenlaub V, Fischer RJ. et al. Risk-profile and outcome of small papillary and follicular thyroid carcinomas (<1 cm). Nuklearmedizin 2008; 47: 188-193.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Riemann B, Schober O. Are “high-risk” patients with differentiated thyroid cancer “healthy patients”?. Nuklearmedizin 2008; 47: 179-180.
    PubMedGoogle Scholar
  • 24 Saur HB, Lerch H, Schober O. The survival rate of patients with a differentiated thyroid carcinoma without primary percutaneous irradiation of the neck area. Strahlenther Onkol 1996; 172: 306-311.
    PubMedGoogle Scholar
  • 25 Sautter-Bihl ML, Herbold G, Heinze HG, Bihl H. Postoperative external beam radiation in differentiated thyroid cancer: situations in which radioiodine is insufficient? Some dosimetric considerations with Monte Carlo techniques. Strahlenther Onkol 1991; 167: 267-272.
    PubMedGoogle Scholar
  • 26 Schmoor C, Olschewski M, Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med 1996; 15: 263-271.
    CrossrefPubMedGoogle Scholar
  • 27 Schuck A, Biermann M, Pixberg MK. et al. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid cancer: First results of the Multicenter Study Differentiated Thyroid Cancer. Strahlenther Onkol 2003; 179: 821-827.
    Google Scholar
  • 28 Seegenschmiedt MH, Sautter-Bihl ML, Schmitt G. et al. Guidelines in radiooncology. External beam radiotherapy of malignant struma. AWMF-Guideline registry no. 052/001 1998
    PubMedGoogle Scholar
  • 29 Sherman SI, Brierley JD, Sperling M. et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998; 83: 1012-1021.
    Google Scholar
  • 30 Simpson WJ, Panzarella T, Carruthers JS. et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14: 1063-1075.
    CrossrefPubMedGoogle Scholar
  • 31 Tsang RW, Brierley JD, Simpson WJ. et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82: 375-388.
    CrossrefPubMedGoogle Scholar
  • 32 Wittekind C. TNM Supplement: A commentary on uniform use (UICC). 3rd ed. 2003
    PubMedGoogle Scholar
  • 33 Wittekind C, Meyer HJ, Bootz F. TNM classification of malignant tumors. 6th ed. Berlin: Springer; 2002
    Google Scholar
  • 34 Wittekind C, Wagner G. TNM classification of malignant tumors. 5th ed. Berlin: Springer; 1997
    Google Scholar
  • 35 Wu XL, Hu YH, Li QH. et al. Value of postoperative radiotherapy for thyroid cancer. Head Neck Surg 1987; 10: 107-112.
    CrossrefPubMedGoogle Scholar